N-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease

Journal of Hypertension

Volumn 33, Issue 9, 2015, Pages 1947-1953

  Barden, Anne E ^a   Burke, Valerie ^a   Mas, Emilie ^a   Beilin, Lawrence J ^a   Puddey, Ian B ^a   Watts, Gerald F ^a   Irish, Ashley B ^b   Mori, Trevor A ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

20 hydroxyeicosatetraenoic acid; Chronic kidney disease; F2 isoprostanes; N 3 fatty acid supplementation

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ISOPROSTANE DERIVATIVE; NITRATE; NITRITE; OLIVE OIL; OMEGA 3 ACID ETHYL ESTER; UBIDECARENONE; 20-HYDROXY-5,8,11,14-EICOSATETRAENOIC ACID; HYDROXYICOSATETRAENOIC ACID; OMEGA 3 FATTY ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINE LEVEL; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; DIETARY SUPPLEMENT; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; URINE;

ADULT; AGED; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; F2-ISOPROSTANES; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84942570588     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000621     Document Type: Article

References (38)

1. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002; 82:131-185.
2. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA. Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol Renal Physiol 2000; 279:F544-F551.
3. Hercule HC, Oyekan AO. Cytochrome P450 omega/omega-1 hydroxylase-derived eicosanoids contribute to endothelin(A) and endothelin( B) receptor-mediated vasoconstriction to endothelin-1 in the rat preglomerular arteriole. J Pharmacol Exp Ther 2000; 292:1153-1160.
4. Parmentier JH, Muthalif MM, Saeed AE, Malik KU. Phospholipase D activation by norepinephrine is mediated by 12(s)-, 15(s)-, and 20-hydroxyeicosatetraenoic acids generated by stimulation of cytosolic phospholipase a2. tyrosine phosphorylation of phospholipase d2 in response to norepinephrine. J Biol Chem 2001; 276:15704-15711.
5. Ma YH, Schwartzman ML, Roman RJ. Altered renal P-450 metabolism of arachidonic-acid in dahl salt-sensitive rats. Am J Physiol 1994; 267: R579-R589.
6. Xu FY, Straub WO, Pak W, Su P, Maier KG, Yu M, et al. Antihypertensive effect of mechanism-based inhibition of renal arachidonic acid omega-hydroxylase activity. Am J Physiol Regulat Integr Comp Physiol 2002; 283:R710-R720.
7. De Caterina R. Drug therapy n-3 fatty acids in cardiovascular disease. N Engl J Med 2011; 364:2439-2450.
8. Mas E, Barden A, Durand T, Galano JM, Croft KD, Mori TA. Measurement of urinary F-2-isoprostanes by gas chromatography-mass spectrometry is confounded by interfering substances. Free Radical Res 2010; 44:191-198.
9. Mori TA. Omega-3 fatty acids and blood pressure. Cell Mol Biol (Noisyle-grand) 2010; 56:83-92.
10. Mori TA. Omega-3 fatty acids and hypertension in humans. Clin Exp Pharmacol Physiol 2006; 33:842-846.
11. Mori TA. Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors. Food Funct 2014; 5:2004-2019.
12. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q(10) improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 2002; 56:1137-1142.
13. Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002; 45:420-426.
14. Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am J Cardiol 2002; 90:; 1254-L 1257.
15. Mori TA, Burke V, Puddey IB, Irish AB, Cowpland CA, Beilin LJ, et al. The effects of omega 3 fatty acids and coenzyme Q(10) on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J Hypertens 2009; 27:1863-1872.
16. Rivera J, Ward N, Hodgson J, Puddey IB, Falck JR, Croft KD. Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry. Clin Chem 2004; 50:224-226.
17. Tsai IJ, Croft KD, Mori TA, Falck JR, Beilin LJ, Puddey IB, et al. 20-HETE and F2-isoprostanes in the metabolic syndrome: the effect of weight reduction. Free Radic Biol Med 2009; 46:263-270.
18. Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008; 88:1018-1025.
19. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21:2917-2930.
20. Cheng J, Ou JS, Singh H, Falck JR, Narsimhaswamy D, Pritchard KA, et al. 20-hydroxyeicosatetraenoic acid causes endothelial dysfunction via eNOS uncoupling. Am J Physiol-Heart C 2008; 294:H1018-H1026.
21. Cheng J, Garcia V, Ding Y, Wu C-C, Thakar K, Falck JR, et al. Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2012; 32:1917-2451.
22. Ward NC, Rivera J, Hodgson J, Puddey IB, Beilin LJ, Falck JR, et al. Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 2004; 110:438-443.
23. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radical Bio Med 2005; 38:1032-1036.
24. Shrivas K, Mindaye ST, Getie-Kebtie M, Alterman MA. Mass spectrometry-based proteomic analysis of human liver cytochrome(s) P450. Toxicol Appl Pharmacol 2013; 267:125-136.
25. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney: role of CYP4F2 and CYP4A11. J Biol Chem 2000; 275:4118-4126.
26. Powell PK, Wolf I, Jin RY, Lasker JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 1998; 285:1327-1336.
27. Jarrar YB, Cho SA, Oh KS, Kim DH, Shin JG, Lee SJ. Identification of cytochrome P450 s involved in the metabolism of arachidonic acid in human platelets. Prostag Leukotr Ess 2013; 89:227-234.
28. Kikuta Y, Kusunose E, Endo K, Yamamoto S, Sogawa K, Fujiikuriyama Y, et al. A novel form of cytochrome-P-450 family-4 in human polymorphonuclear leukocytes: cdna cloning and expression of leukotriene-B4 omega-hydroxylase. J Biol Chem 1993; 268:9376-9380.
29. Tsai IJ, Croft KD, Puddey IB, Beilin LJ, Barden A. 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am J Physiol-Heart C 2011; 300:H1194-H1200.
30. Bertrand-Thiebault C, Ferrari L, Boutherin-Falson O, Kockx M, Desquand-Billiald S, Fichelle JM, et al. Cytochromes P450 are differently expressed in normal and varicose human saphenous veins: linkage with varicosis. Clin Exp Pharmacol Physiol 2004; 31:295-301.
31. Fer M, Corcos L, Dreano Y, Plee-Gautier E, Salaun JP, Berthou F, et al. Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J Lipid Res 2008; 49:2379-2389.
32. Prakash C, Zhang JY, Falck JR, Chauhan K, Blair IA. 20-hydroxyeicosatetraenoic acid is excreted as a glucuronide conjugate in human urine. Biochem Bioph Res Co 1992; 185:728-733.
33. Rivera J, Ward N, Hodgson J, Puddey IB, Falck JR, Croft KD. Measurement of 20-hydroxyeicosatetraenoic acid in human urine by gas chromatography-mass spectrometry. Clin Chem 2004; 50:224-226.
34. Minuz P, Jiang H, Fava C, Turo L, Tacconelli S, Ricci M, et al. Altered release of cytochrome P450 metabolites of arachidonic acid in renovascular disease. J Hypertens 2007; 25:S396-S400.
35. Barden AE, Mori TA, Dunstan JA, Taylor AL, Thornton CA, Croft KD, et al. Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy. Free Radic Res 2004; 38:233-239.
36. Mas E, Woodman RJ, Burke V, Puddey IB, Beilin LJ, Durand T, et al. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: results from two placebo-controlled interventions. Free Radic Res 2010; 44:983-990.
37. Mori TA, Dunstan DW, Burke V, Croft KD, Rivera JH, Beilin LJ, et al. Effect of dietary fish and exercise training on urinary F2-isoprostane excretion in noninsulin-dependent diabetic patients. Metabolism 1999; 48:1402-1408.
38. Mori TA, Puddey IB, Burke V, Croft KD, Dunstan DW, Rivera JH, et al. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox Rep 2000; 5:45-46.